Discriminating Between Cardiac and Pulmonary Dysfunction in the General Population With Dyspnea by Plasma Pro-B-Type Natriuretic Peptide

Journal of the American College of Cardiology

Volumn 50, Issue 17, 2007, Pages 1694-1701

  Mogelvang, Rasmus ^a,b   Goetze, Jens P ^a,b   Schnohr, Peter ^a   Lange, Peter ^a,b   Sogaard, Peter ^b   Rehfeld, Jens F ^b   Jensen, Jan S ^a,b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; OXYGEN SATURATION; PRIORITY JOURNAL; SPIROMETRA; SPIROMETRY; SYSTOLIC DYSFUNCTION;

AGE DISTRIBUTION; BIOLOGICAL MARKERS; CAUSALITY; COHORT STUDIES; COMORBIDITY; DENMARK; DIAGNOSIS, DIFFERENTIAL; DYSPNEA; FEMALE; HEART DISEASES; HUMANS; LONGITUDINAL STUDIES; LUNG DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION;

EID: 35248854631     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.07.073     Document Type: Article

References (29)

1. Pratter M.R., Curley F.J., Dubois J., and Irwin R.S. Cause and evaluation of chronic dyspnea in a pulmonary disease clinic. Arch Intern Med 149 (1989) 2277-2282
2. Remes J., Miettinen H., Reunanen A., and Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 12 (1991) 315-321
3. Davis M., Espiner E., Richards G., et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 343 (1994) 440-444
4. Morrison L.K., Harrison A., Krishnaswamy P., Kazanegra R., Clopton P., and Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 39 (2002) 202-209
5. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
6. Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350 (2004) 647-654
7. Ray P., Arthaud M., Lefort Y., Birolleau S., Beigelman C., and Riou B. Usefulness of B-type natriuretic peptide in elderly patients with acute dyspnea. Intensive Care Med 30 (2004) 2230-2236
8. Chen A.A., Wood M.J., Krauser D.G., et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J 27 (2006) 839-845
9. Mueller C., Laule-Kilian K., Schindler C., et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 166 (2006) 1081-1087
10. Appleyard M., Hansen A.T., Schnohr P., Jensen G., and Nyboe J. The Copenhagen City Heart Study. A book of tables with data from the first examination (1976-78) and a five-year follow-up (1981-83). Scand J Soc Med 170 (1989) 1-160
11. Schnohr P., Jensen G., Lange P., Scharling H., and Appleyard M. The Copenhagen City Heart Study. Tables with data from the third examination 1991-94. Eur Heart J 3 (2001) 1-83
12. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
13. Peters A.L., Davidson M.B., Schriger D.L., and Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA 276 (1996) 1246-1252
14. Rowley K.G., Daniel M., and O'Dea K. Screening for diabetes in Indigenous populations using glycated haemoglobin: sensitivity, specificity, post-test likelihood and risk of disease. Diabet Med 22 (2005) 833-839
15. Rehfeld J.F., and Goetze J.P. The posttranslational phase of gene expression: new possibilities in molecular diagnosis. Curr Mol Med 3 (2003) 25-38
16. Goetze J.P., Kastrup J., Pedersen F., and Rehfeld J.F. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem 48 (2002) 1035-1042
17. Goetze J.P., Mogelvang R., Maage L., et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J 27 (2006) 3004-3010
18. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
19. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57 (1986) 450-458
20. Du Bois D., and Du Bois E.F. A formula to estimate the approximate surface if height and weight be known. Arch Intern Med 17 (1916) 863-871
21. Devereux R.B., Dahlof B., Levy D., and Pfeffer M.A. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol 78 (1996) 61-65
22. Tei C., Ling L.H., Hodge D.O., et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function-a study in normals and dilated cardiomyopathy. J Cardiol 26 (1995) 357-366
23. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 288 (2002) 1252-1259
24. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett Jr. J.C. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40 (2002) 976-982
25. McDonagh T.A., Holmer S., Raymond I., Luchner A., Hildebrandt P.R., and Dargie H.J. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail 6 (2004) 269-273
26. Costello-Boerrigter L.C., Boerrigter G., Redfield M.M., et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 47 (2006) 345-353
27. Nielsen O.W., McDonagh T.A., Robb S.D., and Dargie H.J. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 41 (2003) 113-120
28. Heidenreich P.A., Gubens M.A., Fonarow G.C., Konstam M.A., Stevenson L.W., and Shekelle P.G. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 43 (2004) 1019-1026
29. Siebert U., Januzzi Jr. J.L., Beinfeld M.T., Cameron R., and Gazelle G.S. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol 98 (2006) 800-805